Checkpoint inhibitor-induced sarcoid choroidal granulomas

Article Properties
Cite
Ung, Cindy, and Evangelos Gragoudas. “Checkpoint Inhibitor-Induced Sarcoid Choroidal Granulomas”. American Journal of Ophthalmology Case Reports, vol. 18, 2020, p. 100652, https://doi.org/10.1016/j.ajoc.2020.100652.
Ung, C., & Gragoudas, E. (2020). Checkpoint inhibitor-induced sarcoid choroidal granulomas. American Journal of Ophthalmology Case Reports, 18, 100652. https://doi.org/10.1016/j.ajoc.2020.100652
Ung, Cindy, and Evangelos Gragoudas. “Checkpoint Inhibitor-Induced Sarcoid Choroidal Granulomas”. American Journal of Ophthalmology Case Reports 18 (2020): 100652. https://doi.org/10.1016/j.ajoc.2020.100652.
Ung C, Gragoudas E. Checkpoint inhibitor-induced sarcoid choroidal granulomas. American Journal of Ophthalmology Case Reports. 2020;18:100652.
Refrences
Title Journal Journal Categories Citations Publication Date
Ocular adverse events with immune checkpoint inhibitors Journal of Current Ophthalmology
  • Medicine: Ophthalmology
 61 2019
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas International Journal of Clinical Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 39 2019
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Annals of Intensive Care
  • Medicine: Internal medicine: Medical emergencies. Critical care. Intensive care. First aid
  • Medicine: Internal medicine: Special situations and conditions
  • Medicine: Internal medicine: Medical emergencies. Critical care. Intensive care. First aid
  • Medicine: Internal medicine: Medical emergencies. Critical care. Intensive care. First aid
  • Medicine: Medicine (General)
 41 2019
Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects 2018
Sarcoid-like reactions in patients receiving modern melanoma treatment Melanoma Research
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Dermatology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 2018
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)12
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens11
Medicine: Internal medicine: Medical emergencies. Critical care. Intensive care. First aid4
Medicine: Ophthalmology3
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system2
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system2
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy2
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology2
Medicine2
Medicine: Internal medicine: Special situations and conditions1
Technology: Chemical technology: Biotechnology1
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs1
Science: Biology (General)1
Science: Chemistry: Organic chemistry: Biochemistry1
Medicine: Dermatology1
The category Medicine: Medicine (General) 12 is the most frequently represented among the references in this article. It primarily includes studies from Ophthalmology and Current Opinion in Oncology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Title Journal Journal Categories Citations Publication Date
Pembrolizumab-Induced Nodular Posterior Scleritis

 Journal of VitreoRetinal Diseases
  • Medicine: Ophthalmology
 2023
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

 Journal of Ophthalmic Inflammation and Infection
  • Medicine: Ophthalmology
  • Medicine: Ophthalmology
 7 2023
Differential diagnosis of pulmonary sarcoidosis: a review

 Frontiers in Medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
 7 2023
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

 Cancers
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1 2023
Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma

 Clinical Case Reports
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 2022
Citations Analysis
Category Category Repetition
Medicine: Medicine (General)5
Medicine: Ophthalmology4
Medicine: Internal medicine2
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens2
The category Medicine: Medicine (General) 5 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Nivolumab and was published in 2020. The most recent citation comes from a 2023 study titled Differential diagnosis of pulmonary sarcoidosis: a review. This article reached its peak citation in 2023, with 4 citations. It has been cited in 9 different journals, 33% of which are open access. Among related journals, the Journal of Ophthalmic Inflammation and Infection cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year